Skip to main content

Invitrogen, Proctor & Gamble Pharma Extend RNAi Pact Through 2006

This article corrects an earlier version that contained inaccurate information. The original said the agreement runs through 2008.

 

NEW YORK, Nov. 2 (GenomeWeb News) - Invitrogen and Proctor & Gamble Pharmaceuticals have extended a research service agreement through 2006, the firms said today.

 

The agreement extends a collaboration between the two companies that is several years old.

 

According to Invitrogen's CEO Greg Lucier, P&GP has been using Invitrogen's RNAi tools such as Stealth, RNAi Gateway, and lentiviral vectors in its target-identification and -validation programs.

 

Financial details were not discussed.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.